John Gill

CIK: 0001409939

Transaction Breakdown

Open Market Buys (P)2 (33.3%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)3 (50.0%)

Compensation grants

Other (G, F, J, C, D, …)1 (16.7%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

ALT

Altimmune, Inc.

Director

Discretionary Trading P&L

Holdings

Transaction History (6 total)

ALT
Altimmune, Inc.
May 1, 2026
Award(A)
Stock Options (option to buy)
Direct
48.8K shares-
ALT
Altimmune, Inc.
Apr 6, 2026
Purchase(P)
Direct
9.2K shares at avg. $3.41$31K
ALT
Altimmune, Inc.
Dec 23, 2025
Purchase(P)
Direct
12.5K shares at avg. $4.10$51K
ALT
Altimmune, Inc.
Sep 25, 2025
Award(A)
Stock Options (option to buy)
Direct
48.8K shares-
ALT
Altimmune, Inc.
Sep 26, 2024
Award(A)
Stock Options (option to buy)
Direct
34.9K shares-
ALT
Altimmune, Inc.
Jan 6, 2022
Gift(G)
Direct
2.7K shares-

		Type	Shares	Price		Ownership
May 1, 2026	ALT Altimmune, Inc.	Award(A) Stock Options (option to buy)	48,800	-	-	Direct
Apr 6, 2026	ALT Altimmune, Inc.	Purchase(P)	9,200	$3.41	$31,350	Direct
Dec 23, 2025	ALT Altimmune, Inc.	Purchase(P)	12,500	$4.10	$51,250	Direct
Sep 25, 2025	ALT Altimmune, Inc.	Award(A) Stock Options (option to buy)	48,800	-	-	Direct
Sep 26, 2024	ALT Altimmune, Inc.	Award(A) Stock Options (option to buy)	34,900	-	-	Direct
Jan 6, 2022	ALT Altimmune, Inc.	Gift(G)	2,714	-	-	Direct

1-6 of 6 transactions

About GILL JOHN

GILL JOHN (SEC CIK 0001409939) files insider reports with the SEC as Director of Altimmune, Inc. (ALT).

Signal8 holds 5 ownership filings by GILL JOHN, all Form 4s, filed between Sep 30, 2024 and May 1, 2026. Those filings report 6 transactions, from Jan 6, 2022 to May 1, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on GILL JOHN's filings is in GAITHERSBURG, MD.

Recent filings by GILL JOHN

May 1, 2026: Grant or award of ALT derivative securities (Form 4, code A).
Apr 6, 2026: Open-market purchase of ALT shares (Form 4, code P).
Dec 23, 2025: Open-market purchase of ALT shares (Form 4, code P).
Sep 25, 2025: Grant or award of ALT derivative securities (Form 4, code A).
Sep 26, 2024: Grant or award of ALT derivative securities (Form 4, code A).

Other insiders filing for Altimmune, Inc. (ALT)

Arbet-Engels Christophe, Chief Medical Officer
WEAVER GREGORY L, Chief Financial Officer
MENZIUSO RICHARD THOMAS, Principal Accounting Officer
Richardson Linda M, Chief Commercial Officer
Durso Jerome Benedict, President and CEO
Roberts M Scot, Chief Scientific Officer

How to read Form 4 transaction codes